Found: 15
Select item for more details and to access through your institution.
Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa.
- Published in:
- PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0204899
- By:
- Publication type:
- Article
Thrombotic thrombocytopenic purpura: A 5‐year tertiary care centre experience.
- Published in:
- Journal of Clinical Apheresis, 2019, v. 34, n. 1, p. 44, doi. 10.1002/jca.21673
- By:
- Publication type:
- Article
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
- Published in:
- Haemophilia, 2021, v. 27, n. 6, p. e772, doi. 10.1111/hae.14421
- By:
- Publication type:
- Article
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study.
- Published in:
- Haemophilia, 2021, v. 27, n. 3, p. 398, doi. 10.1111/hae.14270
- By:
- Publication type:
- Article
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
- Published in:
- Haemophilia, 2021, v. 27, n. 2, p. 221, doi. 10.1111/hae.14222
- By:
- Publication type:
- Article
Redefining prophylaxis in the modern era.
- Published in:
- Haemophilia, 2021, v. 27, p. 21, doi. 10.1111/hae.14035
- By:
- Publication type:
- Article
Requirements to participate in haemophilia clinical trials.
- Published in:
- Haemophilia, 2020, v. 26, p. 22, doi. 10.1111/hae.13886
- By:
- Publication type:
- Article
The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
- Published in:
- Haemophilia, 2019, v. 25, n. 1, p. 33, doi. 10.1111/hae.13618
- By:
- Publication type:
- Article
Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing.
- Published in:
- Clinical Laboratory, 2019, v. 65, n. 4, p. 659, doi. 10.7754/Clin.Lab.2018.180919
- By:
- Publication type:
- Article
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
- Published in:
- BioDrugs, 2018, v. 32, n. 6, p. 561, doi. 10.1007/s40259-018-0315-0
- By:
- Publication type:
- Article
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. 229, doi. 10.1111/bjh.18420
- By:
- Publication type:
- Article
Long-acting recombinant factor IX Fc fusion protein ( rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 1, p. 124, doi. 10.1111/bjh.13112
- By:
- Publication type:
- Article
Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa.
- Published in:
- International Journal of Nephrology & Renovascular Disease, 2019, v. 12, p. 19, doi. 10.2147/IJNRD.S179802
- By:
- Publication type:
- Article
Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 11, p. 335, doi. 10.1177/2040620718802606
- By:
- Publication type:
- Article
BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 7, p. 191, doi. 10.1177/2040620718777903
- By:
- Publication type:
- Article